Search hospitals > Ohio > Columbus
The Mark H Zangmeister Center
Claim this profileColumbus, Ohio 43219
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
275 reported clinical trials
7 medical researchers
Summary
The Mark H Zangmeister Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. The Mark H Zangmeister Center is involved with conducting 275 clinical trials across 410 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Jeanna L Knoble, Sameh Mikhail, MD, and Emily Whitman.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
Jeanna L KnobleZangmeister Cancer Center2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
3 reported clinical trials
11 drugs studied
Sameh Mikhail, MDZangmeister Cancer Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Ovarian Cancer
2 reported clinical trials
3 drugs studied
Emily WhitmanZangmeister Cancer Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
2 reported clinical trials
4 drugs studied
Clinical Trials running at The Mark H Zangmeister Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Carcinoma
Melanoma
Cutaneous Melanoma
Tumors
Bladder Cancer
Pancreatic Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at The Mark H Zangmeister Center?
The Mark H Zangmeister Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. The Mark H Zangmeister Center is involved with conducting 275 clinical trials across 410 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Jeanna L Knoble, Sameh Mikhail, MD, and Emily Whitman.